Vitamin D therapy in patients with chronic renal disease: The role of the renal dietitian

Advances in Renal Replacement Therapy

Volumn 7, Issue 4, 2000, Pages 358-364

  Sadler, R ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Nutritional guidelines; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D analogs; Vitamin D hormone

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

CHRONIC KIDNEY DISEASE; DIETARY INTAKE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MALNUTRITION; MINERAL BALANCE; NUTRITIONAL STATUS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 0033770519     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2000.16272     Document Type: Article

References (53)

1. Vitamin D analogues
2. Bone mineral density and Abiochemical markers of bone turnover in patients with predialysis chronic renal failure
3. Pathogenesis of secondary hyperparathyroidism
4. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure
5. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients
6. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
7. Hyperphosphatemia and not hypercalcemia is the major factor in the therapeutic failure of dialysis patients with hyperparathyroid bone disease
8. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism
9. Hyperphosphatemia: A serious limiting factor preventing the possible benefit from intravenous calcitriol therapy
10. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism
11. The treatment of renal osteodystrophy: Optimizing outcomes
12. Toward a new treatment paradigm for hyperphosphatemia in chronic renal disease
13. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study
14. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients
15. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease
16. Hyperphosphataemia - A silent killer of patients with renal failure?
17. Seasonal variation in vitamin D
18. 1 α-Hydroxy-vitamin D2: A new look at an 'old' compound
19. Mechanism of vitamin D action and its regulation
20. Serum levels of 1,25-dihydroxyvitamin D,24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure
21. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients
22. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure
23. Renal bone disease - An ongoing challenge to the nephrologist
24. Monoclonality of parathyroid tumors in chronic renal failure in primary parathyroid hyperplasia
25. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphate
26. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
27. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol
28. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
29. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients
30. Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
31. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety
32. Secondary hyperparathyroidism in patients from Western Australia with hip fracture: Relationship to type of hip fracture, renal function, and vitamin D deficiency
33. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
34. Intermittent oral 1-α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients
35. 2
36. 2, calcitriol, and calcipotriol
37. 2 detectable in human serum
38. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
39. Prevention of renal osteodystrophy in predialysis patients
40. Prevention, diagnosis and treatment of renal osteodystrophy in Spain. Preliminary results from a multicentre enquiry
41. Prevention of metabolic bone disease in the pre-end-stage renal disease setting
42. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure
43. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure
44. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
45. Current and future therapies for the medical management of secondary hyperparathyroidism
46. Secondary hyperparathyroidismi: Defining a model of optimal management
47. Pathogenesis and treatment of secondary hyperparathyroidism in chronic renal disease
48. 2
49. Update on renal osteodystrophy: Pathogenesis and clinical management
50. A multidisciplinary approach to the control of the calcium X phosphate product in dialysis patients
51. Contracting with outpatient hemodialysis patients to improve adherence to treatment
52. Clinical outcome of calcitriol therapy and patient education program on hyperparathyroidism